Ginkgo Bioworks Holdings Inc. Class A Common Stock Earnings Recaps
Q3 2025
Nov 8, 2025
Ginkgo Bioworks reported a significant reduction in cash burn and reaffirmed its 2025 revenue guidance, despite a challenging environment in the biotechnology sector.
Key takeaways
- Quarterly cash burn decreased by 75% year-over-year to $28 million, significantly improving the company's cash position with $462 million in cash and no bank debt.
- Cell Engineering revenue fell 61% year-over-year to $29 million due to a previous noncash revenue spike; adjusted revenue was down only 11% compared to the prior year.
- Biosecurity revenue reached $9 million with a gross margin of 19%, and segment operating loss improved by 21% from a year prior.
- The company remains focused on expansion in AI and automation, with plans to deliver autonomous labs at customer sites.
- Ginkgo reaffirmed its full-year 2025 revenue guidance between $167 million and $187 million, with expectations for Cell Engineering revenue to range from $117 million to $137 million.
Q2 2025
Aug 8, 2025
Ginkgo Bioworks reported a significant reduction in cash burn and costs, achieving a $250 million annual run rate savings three months ahead of schedule while guiding for continued revenue growth in 2025.
Key takeaways
- Cell Engineering revenue increased by 8% year-over-year to $39 million, with a 10% rise in revenue-generating programs.
- Total adjusted EBITDA improved by 72%, reducing losses to $28 million from $99 million a year ago.
- Successful restructuring resulted in a 63% decrease in R&D expenses and a 57% drop in G&A expenses.
- Cash burn was reduced to $38 million, down from $110 million in the same quarter last year, enabling a stronger cash position of $474 million.
- Full-year revenue guidance for 2025 remains unchanged, with expectations of $167 million to $187 million, reflecting strategic growth initiatives.